ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

2025Äê11ÔÂ9ÈÕ£¬£¬£¬£¬£¬£¬£¬£¬È«Çò°©Ö¢ÃâÒßÖÎÁÆÁìÓò¼«¾ßÓ°ÏìÁ¦µÄ¹ú¼ÊѧÊõÊ¢»á——µÚ40½ì°©Ö¢ÃâÒßÖÎÁÆѧ»á£¨SITC£©Äê»áÔÚÃÀ¹úÔ²ÂúÂäÄ»¡£¡£¡£¡£¡£¡£¡£ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼°ÆäÃÀ¹ú¹«Ë¾Chantibody Therapeutics×é³ÉµÄÖÐÃÀЭͬÍŶÓÔÚ¹ú¼ÊѧÊõƽ̨ÉÏÐû²¼ÁËCT111ºÍCT224Á½¿îÁ¢ÒìÃâÒßÖÎÁÆÒ©ÎïµÄÁÙ´²Ç°Êý¾Ý¡£¡£¡£¡£¡£¡£¡£

ÕâÁ½¿îÒ©Îï¾ùÔ´×Ô½üÆÚÕ¶»ñÖÐÃÀ˫רÀûµÄµÚËÄ´úÄÉÃ׿¹ÌåVHHMAb®Æ½Ì¨£¬£¬£¬£¬£¬£¬£¬£¬ÒԓרÀûƽ̨+¹ÜÏß¿ª·¢”µÄЧ¹ûÂäµØ£¬£¬£¬£¬£¬£¬£¬£¬ÇåÎúÕ¹ÏÖÁË´Ó»ù´¡Ñо¿µ½Ó¦ÓÃת»¯µÄ¸ßЧ·¾¶£¬£¬£¬£¬£¬£¬£¬£¬ÎªÊµÌåÖ×ÁöÖÎÁÆ´øÀ´¾ßÓвî±ð»¯ÓÅÊƵĽâ¾ö¼Æ»®¡£¡£¡£¡£¡£¡£¡£

CT111£ºÈýÌØÒìÐÔ¿¹ÌåʵÏÖÈýÖØ»úÖÆЭͬ¿¹°© ÆƽâʵÌåÁöÖÎÁÆÆ¿¾±

ÕªÒª±àºÅ£º976

ÕªÒªÎÊÌ⣺CT111, a PD-1 x CTLA-4 x VEGF trispecific antibody, demonstrates potent anti-tumor efficacy through synergistic immune checkpoint blockade and VEGF inhibition with cooperative avidity

CT111ÊÇÒ»¿î°ÐÏòPD-1¡¢CTLA-4ºÍVEGFµÄÈýÌØÒìÐÔ¿¹Ì壬£¬£¬£¬£¬£¬£¬£¬Í¨¹ý¼òµ¥È«VHH·Ö×ÓʵÏÖÒÖÖÆÖ×ÁöѪ¹ÜÌìÉúЭͬ¼¤»îTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬£¬£¬´ú±íÏÂÒ»´úÃâÒßÖÎÁƵÄÆ«Ïò¡£¡£¡£¡£¡£¡£¡£¸ÃÑо¿ÓÉChantibodyǣͷ£¬£¬£¬£¬£¬£¬£¬£¬ÖÐÃÀÍŶӷֹ¤Ð­×÷¸ßЧÍê³É¹¥¹Ø¡£¡£¡£¡£¡£¡£¡£

Åä¾°ÏÈÈÝ£ºPD-1¡¢CTLA-4ºÍVEGFÊÇÖ×ÁöÃâÒßÖÎÁÆÖÐÒÑ»ñÁÙ´²ÑéÖ¤µÄÒªº¦°Ðµã£¬£¬£¬£¬£¬£¬£¬£¬ÈýÕßÔÚ¿¹Ö×ÁöÃâÒßÑ­»··´Ó¦ÖÐÊ©Õ¹»¥²¹×÷Óᣡ£¡£¡£¡£¡£¡£ÏÖÔÚË«ÌØÒìÐÔ¿¹ÌåºÍ¶à°ÐµãÍŽáÖÎÁÆËäÒÑÕ¹ÏÖÁÙ´²Ç±Á¦£¬£¬£¬£¬£¬£¬£¬£¬µ«ÔÚ¿¹Ö×ÁöÁÆЧһÁ¬ÐÔºÍ×ÜÌåÉúÑÄ»ñÒæÉÏÈÔÓвî±ð¡£¡£¡£¡£¡£¡£¡£CT111ͨ¹ý¶àÌØÒìÐÔ¿¹ÌåµÄЭͬÍŽáÌØÕ÷£¬£¬£¬£¬£¬£¬£¬£¬½«¿¹PD-1£¨»Ö¸´Ð§Ó¦TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾»îÐÔ£©¡¢¿¹CTLA-4£¨TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Æô¶¯/ÔöÖ³£©ÒÔ¼°¿¹VEGF£¨ÒÖÖÆÖ×ÁöѪ¹ÜÌìÉú£©¹¦Ð§¼¯ÓÚÒ»Ì壬£¬£¬£¬£¬£¬£¬£¬ÓÐÍûʵÏÖ¸üÓŵÄÉúÎïѧЭͬЧӦÓëÁÙ´²»ñÒæ¡£¡£¡£¡£¡£¡£¡£

·Ö×ÓÉè¼ÆÓë»úÖÆ£º

½èÖú¶àÑùÐÔ¿¹Ìå·¢Ã÷ºÍAIÉè¼ÆÄ£¿£¿£¿£¿£¿£¿é£¬£¬£¬£¬£¬£¬£¬£¬Ñз¢ÍŶÓÀֳɹ¹½¨³öË«¼ÛÈý°ÐµÄ¶Ô³Æ¶þ¾Û¿¹Ìå½á¹¹£¬£¬£¬£¬£¬£¬£¬£¬½«¿¹Ö×ÁöÌØÒìÐÔTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼¤»î£¨CTLA-4£©£¬£¬£¬£¬£¬£¬£¬£¬Ö×ÁöÒÖÖƺÍTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾½þÈó£¨VEGF£©£¬£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°Ö×Áö΢ÇéÐε÷¿Ø£¨PD-1£©Èý´ó½¹µã»úÖƸßЧÈںϣ¬£¬£¬£¬£¬£¬£¬£¬Ðγɓ¹¥·À¼æ±¸”µÄЭͬ¿¹°©Ð§Ó¦¡£¡£¡£¡£¡£¡£¡£

ÁÙ´²Ç°ÌåÍâÊý¾Ý: 

CT111¹ØÓÚVEGFµÄ×è¶Ï»îÐÔ±ÈÆäËûVEGFË«¿¹ºÍÈý¿¹²úÆ·ºá¿ç4-5±¶£¬£¬£¬£¬£¬£¬£¬£¬¾ßÓÐPD-1£¬£¬£¬£¬£¬£¬£¬£¬CTLA-4ºÍVEGFÈý°ÐµãÉúÎïѧ»îÐÔºÍÁÙ´²¼ÁÁ¿¸ß¶ÈƽºâµÄÓÅÊÆ£¬£¬£¬£¬£¬£¬£¬£¬¿ÉÒÔ½â¾ö»ñÅúVEGFµ¥¿¹ÁÙ´²¼ÁÁ¿£¨10-15mg/kg£©Áè¼ÝPD-1»òCTLA-4µ¥¿¹¹ØÓÚË«¿¹Èý¿¹¼ÁÁ¿Ñ¡ÔñµÄÄæ¾³£¬£¬£¬£¬£¬£¬£¬£¬Ó뾺ƷÏà±È¾ßÓиüÇ¿µÄ²úÆ·ÓÅÊƺÍÁÙ´²ÓÅÊÆ£¬£¬£¬£¬£¬£¬£¬£¬¿ÉÍØ¿íÇå¾²ÓÐÓõÄÖÎÁÆ´°¿Ú¡£¡£¡£¡£¡£¡£¡£CT111¸ü½øÒ»²½Õ¹ÏÖ³öÆæÒìµÄ“Ç׺ÍÁ¦Ð­Í¬Ð§Ó¦”£¬£¬£¬£¬£¬£¬£¬£¬ÓëVEGFÍŽáºó£¬£¬£¬£¬£¬£¬£¬£¬¼ÈÄÜÏÔÖøÔöÇ¿¶ÔPD-1£¨129±¶£©ºÍCTLA-4£¨15±¶£©µÄÍŽáºÍ×è¶ÏÄÜÁ¦£¬£¬£¬£¬£¬£¬£¬£¬ÓÖ×èÖ¹Á˾ºÆ·±¬·¢µÄ¶à¾ÛÌå·ÇÌØÒìÍŽáÕ÷Ï󣬣¬£¬£¬£¬£¬£¬£¬ÊµÏÖÁË1+1+1 > 3µÄ¾«×¼Ð­Í¬¿¹°©Ð§¹û¡£¡£¡£¡£¡£¡£¡£

ÁÙ´²Ç°ÌåÄÚÊý¾Ý: 

ÔÚÌåÄÚʵÑéÖУ¬£¬£¬£¬£¬£¬£¬£¬µÍ¼ÁÁ¿CT111ÔÚ¶àÖÖÖ×ÁöÄ£×ÓÖÐʵÏÖÁ˳¤ÆÚµÄÖ×ÁöÏûÍ˺ÍÃâÒßÓ°Ï󣬣¬£¬£¬£¬£¬£¬£¬ÁÆЧÏÔÖøÓÅÓÚÁÙ´²±ê¸Ë¿¹Ìå¡£¡£¡£¡£¡£¡£¡£¶ÔHCC827Ö×Áö×éÖ¯µÄÆÊÎöÏÔʾ£¬£¬£¬£¬£¬£¬£¬£¬CT111ÖÎÁƺóÏà¶ÔPD-1/VEGFË«¿¹¾ºÆ·Õë¶ÔÖ×ÁöɱÉ˵ĻCD8+ TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÊýÄ¿ÔöÌí£¬£¬£¬£¬£¬£¬£¬£¬ÃâÒßÒÖÖƵĵ÷ÀíÐÔTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¨Treg£©ÊýÄ¿ïÔÌ­£¬£¬£¬£¬£¬£¬£¬£¬Åú×¢CT111ÖÐCTLA-4×è¶Ï¹¦Ð§¹ØÓÚ¿¹Ö×ÁöµÄÏìÓ¦ºÍ³¤ÆÚÆðµ½ÁËÒªº¦×÷Óᣡ£¡£¡£¡£¡£¡£³ýÁËÏÔÖøµÄÁÆЧ£¬£¬£¬£¬£¬£¬£¬£¬ÓÉÓÚCT111ȱ·¦FcЧӦ¹¦Ð§£¬£¬£¬£¬£¬£¬£¬£¬×èÖ¹ÁËÕý³£×éÖ¯ÖÐTregµÄÏû³ý£¬£¬£¬£¬£¬£¬£¬£¬ÎªÆäÃâÒßÇå¾²ÐÔÌṩÁËÖ÷Òª°ü¹Ü¡£¡£¡£¡£¡£¡£¡£

Ñо¿ÍŶÓÖ¸³ö£¬£¬£¬£¬£¬£¬£¬£¬CT111ͨ¹ýЭͬ×÷ÓÃÔöÇ¿Ö×ÁöÌØÒìTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÔöÖ³£¬£¬£¬£¬£¬£¬£¬£¬½þÈóºÍ¼¤»î£¬£¬£¬£¬£¬£¬£¬£¬ÓÅ»¯Èý°ÐµãÍŽáºÍÉúÎïѧ»îÐÔµÄЭµ÷ƽºâ£¬£¬£¬£¬£¬£¬£¬£¬ÊµÏÖÖ×Áö΢ÇéÐÎÄÚ»îÐÔºÍÁÙ´²Çå¾²ÓÐÓÃÖÎÁÆ´°¿ÚµÄ·Å´ó¡£¡£¡£¡£¡£¡£¡£ÕâЩ·¢Ã÷ΪCT111½øÈëʵÌåÁöÁÙ´²¿ª·¢£¬£¬£¬£¬£¬£¬£¬£¬ÓÈÆäÊÇÕë¶ÔPD-1ÄÍÒ©»¼ÕßµÄÖÎÁƺÍÐÂÒ»´úPD-1¶à¿¹Ò©ÎïµÄ¿ª·¢ÌṩÁ˼áʵÒÀ¾Ý¡£¡£¡£¡£¡£¡£¡£

CT224£ºË«±íλTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÏνÓÆ÷¼æ¹ËÁÆЧÓëÇå¾²£¬£¬£¬£¬£¬£¬£¬£¬Í»ÆƽáÖ±³¦°©ÖÎÁƾÖÏÞ

ÕªÒª±àºÅ£º958

ÕªÒªÎÊÌ⣺CT224: A biparatopic VHH-based CDH17×CD3 T cell engager with optimized safety and efficacy for colorectal cancer

CT224ÊÇÒ»¿î°ÐÏòCDH17Ë«»¥²¹±íλµÄCD3 TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÏνÓÆ÷£¨TCE£©¡£¡£¡£¡£¡£¡£¡£ ͨ¹ýË«±íλÍŽáʵÏÖ¶ÔÖ×ÁöµÄ¸ßÌØÒìÐÔ궨£¬£¬£¬£¬£¬£¬£¬£¬²¢Ê¹ÓÃɸѡÓÅ»¯µÄµÍÇ׺ÍÁ¦¿¹CD3ÄÉÃ׿¹Ìå½µµÍ¹Å°åTCEµÄ¶¾ÐÔΣº¦¡£¡£¡£¡£¡£¡£¡£

CT224µÄÁ¢ÒìÉè¼ÆÖ¼ÔÚÆƽâ¹Å°åTCEÔÚʵÌåÁöÖÎÁÆÖГÁÆЧȱ·¦¡¢¶¾ÐÔÆ«¸ß”µÄÍ´µã£¬£¬£¬£¬£¬£¬£¬£¬Îª½â¾öTCEÔÚʵÌåÁöÖÎÁÆÖеÄÌôÕ½ÌṩÐÂÕ½ÂÔ¡£¡£¡£¡£¡£¡£¡£¸ÃÑо¿Í¬ÑùÓÉChantibody Therapeutics¹«Ë¾Ç£Í·£¬£¬£¬£¬£¬£¬£¬£¬ÖÐÃÀÍŶӷֹ¤Ð­×÷¸ßЧÍê³É¹¥¹Ø¡£¡£¡£¡£¡£¡£¡£

Åä¾°ÏÈÈÝ£º

½áÖ±³¦°©ÊÇÈ«Çò¹æÄ£ÄÚÖØ´óµÄδ±»Öª×ãÒ½ÁÆÐèÇ󣬣¬£¬£¬£¬£¬£¬£¬¸ÆÕ³ÂÑ°×-17£¨CDH17£©ÔÚ´ó´ó¶¼½áÖ±³¦°©Öи߱í´ï£¬£¬£¬£¬£¬£¬£¬£¬Óë²»Á¼Ô¤ºó¼°ÉúÑÄÆÚËõ¶ÌÏà¹Ø¡£¡£¡£¡£¡£¡£¡£ÔÚÕý³£³¦µÀ×éÖ¯ÖУ¬£¬£¬£¬£¬£¬£¬£¬CDH17¾ÖÏÞÓÚϸÃÜÅþÁ¬£¬£¬£¬£¬£¬£¬£¬£¬¶øÔÚÖ×ÁöÖÐÒì³£¸ß±í´ïÇÒ¶¨Î»¸Ä±ä£¬£¬£¬£¬£¬£¬£¬£¬Ê¹Æä³ÉΪÀíÏëµÄÖ×ÁöÖÎÁưеã¡£¡£¡£¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬£¬ÏÖÓÐTCEÔÚʵÌåÁöÖеÄÓ¦ÓÃÊÜÏÞÓڰеãÌØÒìÐÔȱ·¦¡¢CD3¿¹Ìå»îÐÔµ÷¿ØÄÑÌâ¼°Ö×Áö´©Í¸ÐÔ²îµÈÎÊÌâ¡£¡£¡£¡£¡£¡£¡£

·Ö×ÓÉè¼ÆÓë»úÖÆ£º

»ùÓÚµÚËÄ´úÄÉÃ׿¹ÌåVHHMAb®Æ½Ì¨£¬£¬£¬£¬£¬£¬£¬£¬Ñо¿ÍŶÓÀֳɻñµÃÁËÁýÕÖCDH17Æ߸ö°ûÍâÓòÇ׺ÍÁ¦²î±ðǧ±¶µÄCDH17 VHH¿¹Ìå¿â£¬£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°¾ß±¸²î±ðCD3ÍŽá»îÐÔµÄCD3 VHH¿¹Ìå¿â¡£¡£¡£¡£¡£¡£¡£Ê¹ÓÃAIƽ̨Éè¼ÆÒÔ¼°¸ßͨÁ¿¹¦Ð§É¸Ñ¡£¬£¬£¬£¬£¬£¬£¬£¬ÏµÍ³ÐԵĶÔCDH17Ë«±íλ¡¢CD3¿¹ÌåÑ¡ÔñÒÔ¼°LinkerÑ¡Ôñ£¬£¬£¬£¬£¬£¬£¬£¬¾ÙÐÐÉè¼ÆÓëÓÅ»¯¡£¡£¡£¡£¡£¡£¡£×îÖÕºòÑ¡·Ö×ÓCT224Õ¹ÏÖ³öǿЧµÄÖ×ÁöɱÉËÄÜÁ¦¡£¡£¡£¡£¡£¡£¡£

ÁÙ´²Ç°ÌåÍâÊý¾Ý£º

ÔÚCD8TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾½éµ¼µÄÌåÍâTDCCʵÑéÖУ¬£¬£¬£¬£¬£¬£¬£¬Ïà¹ØÓÚµ¥±íλ¿¹ÌåºÍARB202 £¨Benchmark£©£¬£¬£¬£¬£¬£¬£¬£¬Ë«±íλCT224Õ¹ÏÖ³öpM¼¶±ðµÄEC50£¬£¬£¬£¬£¬£¬£¬£¬Åú×¢Æä¾ß±¸¼«Ç¿µÄÖ×ÁöɱÉË»îÐÔ¡£¡£¡£¡£¡£¡£¡£ÔÚPBMCÎÞ°ÐÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¹²·õÓýʵÑéÖУ¬£¬£¬£¬£¬£¬£¬£¬Åä¾°TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼¤»î¼°ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Òò×ÓÊÍ·Åˮƽ¼«µÍ£¬£¬£¬£¬£¬£¬£¬£¬ÌåÏÖ³öÓÅÒìµÄÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£CT224»¹¾ß±¸ÓÅÒìµÄ³ÉÒ©ÐÔÌØÕ÷£¬£¬£¬£¬£¬£¬£¬£¬°üÀ¨1g/LÒÔÉϵĸ߱í´ïÁ¿¡¢¸ß´¿»¯´¿¶È¡¢µÍ¶à·´Ó¦ÐÔ¼°ÓÅÒìµÄÈÈÎȹÌÐÔ£¨Tm¸ßÓÚ65¶È£©£¬£¬£¬£¬£¬£¬£¬£¬ÎªÆä½øÈëÁÙ´²¿ª·¢µÓÚ¨Á˼áʵ»ù´¡¡£¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬£¬£¬CT224µÄ¿¹Ìå¿ÉÓëÈËÔ´¡¢Ê³Ð·ºï¼°ÊóÔ´CDH17½»Ö¯·´Ó¦£¬£¬£¬£¬£¬£¬£¬£¬ÎªÁÙ´²Ç°Ñо¿¼°×ª»¯Ó¦ÓÃÌṩÁ˱㵱¡£¡£¡£¡£¡£¡£¡£

ÁÙ´²Ç°ÌåÄÚÊý¾Ý£º

ÔÚPBMCÈËÔ´»¯Ð¡ÊóCOLO205Ö×ÁöÄ£×Ó£¬£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°HSCÈËÔ´»¯Ð¡ÊóDLD1Ö×ÁöÄ£×ÓÖУ¬£¬£¬£¬£¬£¬£¬£¬CT224µÄÖ×ÁöÉú³¤ÒÖÖÆЧ¹û¾ùÓÅÓÚARB202£¨Benchmark£©£¬£¬£¬£¬£¬£¬£¬£¬²¢ÇҾ߱¸¼ÁÁ¿ÒÀÀµµÄÖ×ÁöÒÖÖÆЧ¹û¡£¡£¡£¡£¡£¡£¡£Í¬Ê±ÔÚʳзºïPKʵÑé̽Ë÷ÖУ¬£¬£¬£¬£¬£¬£¬£¬CT224Õ¹ÏÖ³öÀàIgGµÄ6-7Ìì°ëË¥ÆÚÌØÕ÷£¬£¬£¬£¬£¬£¬£¬£¬Åú×¢ÆäÔÚÈËÌåÄÚ¿ÉÄܾ߱¸ÓÅÒìµÄ¸øҩƵÂÊÓÅÊÆ¡£¡£¡£¡£¡£¡£¡£

Ñо¿½áÂÛÅú×¢£¬£¬£¬£¬£¬£¬£¬£¬CT224×÷ΪÐÂÐÍË«±íλCDH17×CD3 TCE£¬£¬£¬£¬£¬£¬£¬£¬¼æ¾ßǿЧ¿¹Ö×Áö»îÐÔÓëÓÅÒìÇå¾²ÐÔ£¬£¬£¬£¬£¬£¬£¬£¬ÆäС·Ö×ӳߴç¸üÓÐÀûÓÚÖ×Áö´©Í¸£¬£¬£¬£¬£¬£¬£¬£¬ÓÐÓýâ¾öÁËÏÖÓÐTCEÔÚʵÌåÁöÖÎÁÆÖеÄÒªº¦¾ÖÏÞ¡£¡£¡£¡£¡£¡£¡£Æä¿çÎïÖÖ·´Ó¦ÐÔ¡¢ÓÅÒìÒ©´ú¶¯Á¦Ñ§¼°³ÉÒ©ÐÔÌØÕ÷£¬£¬£¬£¬£¬£¬£¬£¬Ö§³ÖÆä×÷ΪÊ׿îÕë¶Ô½áÖ±³¦°©µÄË«±íλTCE¿ªÕ¹½øÒ»²½ÁÙ´²Ç°¿ª·¢¼°ÁÙ´²×ª»¯¡£¡£¡£¡£¡£¡£¡£

ÖÐÃÀЭͬ£º´ÓÊÖÒÕרÀû¹âÁÙ´²Ç±Á¦µÄ¸ßЧת»¯

“ÈôÊÇ˵µÚËÄ´úÄÉÃ׿¹Ìåƽ̨µÄÖÐÃÀ˫רÀûÊÇ‘ÐîÄÜ’£¬£¬£¬£¬£¬£¬£¬£¬ÄÇô´Ë´ÎSITCÐû²¼µÄ˫ҩЧ¹û¾ÍÊÇ‘ÊÍÄÜ’¡£¡£¡£¡£¡£¡£¡£”ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¶­Ê³¤¼æCEOÇ®Æä¾ü½ÌÊÚÌåÏÖ£¬£¬£¬£¬£¬£¬£¬£¬Æ½Ì¨µÄAIÉè¼ÆÓë¸ßÌØÒìÐÔɸѡÓÅÊÆ£¬£¬£¬£¬£¬£¬£¬£¬ÈÃCT111µÄÈý°ÐµãЭͬ¡¢CT224µÄË«±íλ¾«×¼ÍŽá³ÉΪ¿ÉÄÜ£¬£¬£¬£¬£¬£¬£¬£¬¶øÖÐÃÀÍŶӵķֹ¤Ð­×÷Ôò¼ÓËÙÁËЧ¹ûÂäµØ——¼¯ÍÅÒÀÍи»ºñµÄÑòÍÕ×ÊÔ´ºÍ¿¹Ìå·¢Ã÷ÊÖÒÕÌṩ¶àÑù»¯¸ßÖÊÁ¿µÄµ¥°ÐÄÉÃ׿¹Ì壬£¬£¬£¬£¬£¬£¬£¬ChantibodyÒÀ¸½ÃÀ¹ú±¾ÍÁµÄ¿¹Ì幤³ÌÊÖÒÕÓÅÊƺͶ࿹²úÆ·¿ª·¢ÂÄÀúÖ÷¹¥·Ö×ÓÓÅ»¯ºÍ²úÆ·Íƽø£¬£¬£¬£¬£¬£¬£¬£¬ “ÊÖÒÕͬԴ¡¢ÓÅÊÆ»¥²¹”µÄģʽÈÃÁ¢ÒìЧÂʱ¶Ôö¡£¡£¡£¡£¡£¡£¡£

Chantibody×ܲá¢Ê×ϯ¿Æѧ¹ÙÐíÎķ岩ʿÔö²¹µÀ£¬£¬£¬£¬£¬£¬£¬£¬“×÷ΪÖÐÃÀЭͬ¿ª·¢µÄVHHMAb®Æ½Ì¨µÄÖÐÃÀ˫רÀûÊÚȨÒâÒåÖش󣬣¬£¬£¬£¬£¬£¬£¬Ëü²»µ«ÑéÖ¤ÁËÎÒÃǵײãÊÖÒÕµÄÔ­´´ÐÔÓë¹ú¼Ê¾ºÕùÁ¦£¬£¬£¬£¬£¬£¬£¬£¬¸üΪCT111¡¢CT224µÈºóÐø¹ÜÏßÒ©ÎïµÄÈ«Çò¿ª·¢µÓÚ¨ÁËÊÖÒÕ»ù´¡¡£¡£¡£¡£¡£¡£¡£´Ë´Î˫Ч¹ûÁÁÏàSITC£¬£¬£¬£¬£¬£¬£¬£¬Ö¤ÊµÎúÎÒÃǑƽ̨Ñз¢+¾«×¼×ª»¯’ģʽµÄÀֳɣ¬£¬£¬£¬£¬£¬£¬£¬Ò²Õ¹ÏÖÁËÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÓëChantibodyÔڰе㷢Ã÷¡¢¿¹Ì幤³Ì¼°ÁÙ´²Ç°Ñо¿È«Á´ÌõµÄЭͬÓÅÊÆ¡£¡£¡£¡£¡£¡£¡£½ÓÏÂÀ´£¬£¬£¬£¬£¬£¬£¬£¬ÎÒÃǽ«¼ÓËÙÍƽøÁ½¿îÒ©ÎïµÄÁÙ´²×ª»¯£¬£¬£¬£¬£¬£¬£¬£¬´òÔì¸ü¶àÈ«ÇòÊ×´´µÄÖ×ÁöÃâÒßÖÎÁƼƻ®¡£¡£¡£¡£¡£¡£¡£”

×÷ΪȫÇò°©Ö¢ÃâÒßÖÎÁÆÁìÓòµÄÖ÷ҪЭͬʵÁ¦£¬£¬£¬£¬£¬£¬£¬£¬ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÓëChantibodyʼÖÕ±ü³Ö“ÊÖÒÕͬԴ¡¢ÓÅÊÆ»¥²¹”µÄÑз¢ÀíÄ£¬£¬£¬£¬£¬£¬£¬ÒÀÍдӵײãƽ̨µ½Ò©Îï¹ÜÏßµÄÈ«¹¤ÒµÁ´½á¹¹£¬£¬£¬£¬£¬£¬£¬£¬Ò»Á¬Íƶ¯Ö×ÁöÖÎÁÆÊÖÒÕµÄÁ¢ÒìÍ»ÆÆ¡£¡£¡£¡£¡£¡£¡£´Ë´ÎÔÚSITCÄê»áͬ²½Õ¹Ê¾×¨Àûƽ̨ÓëÖØ°õÒ©ÎïЧ¹û£¬£¬£¬£¬£¬£¬£¬£¬²»µ«Õ¹ÏÖÁËÖÐÃÀЭͬÑз¢Ä£Ê½µÄ¸ßЧÐÔ£¬£¬£¬£¬£¬£¬£¬£¬¸üÒԓƽ̨»ñרÀû¡¢Ò©ÎïÏÔÁÆЧ”µÄË«ÖØÍ»ÆÆ£¬£¬£¬£¬£¬£¬£¬£¬ÎªÈ«ÇòÖ×ÁöÃâÒßÖÎÁƵÄÉú³¤×¢Èëж¯ÄÜ¡£¡£¡£¡£¡£¡£¡£